Stentrode is the only implantable brain-computer interface that does not require open brain surgery and is currently in clinical trials SAN FRANCISCO & NEW YORK & MELBOURNE, Australia--(BUSINESS WIRE) ...

California Start-up Synchron recently published its study and findings in the success of the "Stentrode" Brain chips implanted in the blood vessels of paralyzed and disabled patients to help them ...

Synchron, the startup behind an FDA breakthrough neuroprosthesis device that aims to give patients with paralysis the ability to control digital devices with their thoughts, has been cleared by the ...

US-based Synchron has secured $200m in a Series D funding round to drive the commercial rollout of its Stentrode brain-computer interface (BCI) platform and aid in the creation of next-generation ...

Synchron is the only company to receive FDA approval to conduct clinical trials of a permanently implanted BCI. The company’s novel BCI technology leverages the blood vessels as the natural highways ...

SAN FRANCISCO and NEW YORK CITY and MELBOURNE, Australia, Sept. 20 2019 /PRNewswire/ -- Synchron Inc. today announced the first successful clinical implantation of the Stentrode®, a minimally-invasive ...

Even though brain-computer interfaces (BCIs) are still an emerging part of neurotechnology, Neuralink, Elon Musk's BCI startup, has dominated headlines about the space. But rival company Synchron is ...

Neurotech startup Synchron is ramping up production of its flagship brain-computer interface to prepare for commercial demand, as the company inches closer to bringing its device to market. Stream Los ...

Synchron is part of an emerging crop of companies testing technology in the brain-computer interface industry. The system is implanted through the blood vessels and allows patients to operate ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Synchron has raised $200 million to support ...

Neurovascular bioelectronics medicine company Synchron Inc. has received good news in the form of a breakthrough device designation for its Stentrode. The U.S. FDA granted the designation for the ...